MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

168.23B

Vuru Grade

55.06/100

Current Price

$59.55
+0.576 (+0.977%)

Growth Price

$34.60
Overvalued by 41.89%

Stability Price

$19.99
Overvalued by 66.43%

Company Metrics

  • 15.471 P/E
  • 4.024 P/S
  • 3.492 P/B
  • 3.849 EPS
  • 12.10% Cash ROIC
  • 0.84 Cash Ratio
  • 1.8 / 3% Dividend
  • 11.40M Avg. Vol.
  • 2.83B Shares
  • 168.23B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Healthcare Most Active Stocks: Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE ...
StreetWise Report - 11 hours ago
Merck & Co. Inc. (NYSE:MRK) slightly down in last trading session as MSD, known as Merck & Co., Inc. in the U.S.
Merck & Co., Inc. Plans $0.45 Quarterly Dividend (MRK) - WKRB News
Merck & Co. (MRK) - Analysts' Recent Ratings Updates - Mideast Time
Merck & Co. Inc. (MRK) Closes 0.69% Down on the Day for May 26
Equities.com - May 26, 2015
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move -0.69% to $58.97, representing a per-share move of $0.41, on volume of 10.8 million shares for Tuesday.
Active Runners- Mentor Graphics Corp. (NASDAQ:MENT), Merck & Co. Inc ...
StreetWise Report - May 26, 2015
Merck & Co. Inc. (NYSE:MRK) reported that a positive opinion from the Committee for Medicinal Products for Human Use or CHMP for its advanced skin cancer therapy Keytruda or pembrolizumab in patients by means of unresectable or metastatic melanoma.
Merck & Co., Inc. (NYSE:MRK)'s EVP & Pres-Global Human Health Adam ...
OctaFinance.com - May 11, 2015
Two days ago, an insider trading deal was made. Adam Schechter, the EVP & Pres-Global Human Health and an insider of Merck & Co., Inc. (NYSE:MRK) 59.59 +0.62 1.05% sold a total of 10,634 shares of Merck & Co. Inc, worth close to $642,768 USD, ...
Deutsche Bank Reaffirms Hold Rating for Merck & Co. (MRK) - Dakota Financial News
Merck & Co. Given Consensus Recommendation of "Hold" by Brokerages ... - sleekmoney
Earnings Buzz: Pfizer Inc (PFE), Merck & Co Inc (MRK), Bristol-Myers Squibb Co ...
International Business Times - Apr 28, 2015
Pfizer Inc. (NYSE:PFE) shares edged up 0.5 percent Tuesday, despite cutting its full-year 2015 earnings forecast due to a stronger U.S.
Whisper Numbers: Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), And Bristol-Myers ... - Bidness ETC
Pfizer, Merck and Bristol-Myers Squibb Report Solid Results - Wall Street Journal
Investor Alerts- Cerulean Pharma Inc. (NASDAQ:CERU), Merck & Co. Inc. (NYSE ...
StreetWise Report - 13 hours ago
Drug maker, Merck & Co. Inc. (NYSE:MRK) [Trend Analysis] declared on Tuesday that SIMPONI has got CHMP positive opinion for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis or nr-axial SpA with objective ...
Analytic Report on Merck & Co Inc (NYSE:MRK)
Markets Wired - May 8, 2015
[Business Wire] Merck & Co Inc (NYSE:MRK)(TREND ANALYSIS) known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2015.
Merck & Co. Assigned AA Credit Rating (MRK) - Dakota Financial News
Large Cap Stocks to Keep Your Eyes on- Merck (MRK), Bank of America (BAC ... - Techsonian (press release)
Merck & Co., Inc. Raises 2015 Outlook; Q1 Results Beat Estimates On Growth ...
Bidness ETC - Apr 28, 2015
Before the market opened today, pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) announced first-quarter results for fiscal'15, reporting higher-than-expected growth in earnings and revenues, primarily due to increasing sales of its newer drugs.
Bruce Kuhlik just Unloaded 156902 shares of Merck & Co., Inc. (NYSE:MRK ...
OctaFinance.com - Apr 29, 2015
Shareholder Bruce Kuhlik of Merck & Co., Inc. (NYSE:MRK) 59.46 +0.49 0.83% , sold some 156,902 of the firm shares worth $9,386,646 U.S Dollars with an average of $59.8 stock price for a share.
Merck & Co., Inc. (MRK) Issues FY15 Earnings Guidance - Dakota Financial News
Merck & Co. Inc. (MRK) Is Up Sharply After Q1 Profit Surpassed Expectations - Nasdaq
Merck & Co. Inc. (MRK) Closes 1.2% Down on the Day for May 22
Equities.com - May 22, 2015
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move -1.2% to $59.38, representing a per-share move of $0.72, on volume of 8.94 million shares for Friday.